Brokers Offer Predictions for MeiraGTx FY2025 Earnings

MeiraGTx Holdings plc (NASDAQ:MGTX - Free Report) - Research analysts at Chardan Capital issued their FY2025 EPS estimates for MeiraGTx in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will earn $0.25 per share for the year. Chardan Capital has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for MeiraGTx's current full-year earnings is ($1.48) per share.

Separately, Royal Bank of Canada boosted their price objective on shares of MeiraGTx from $11.00 to $13.00 and gave the stock an "outperform" rating in a report on Monday, March 17th.

MeiraGTx Stock Down 0.8 %

MeiraGTx stock traded down $0.06 during trading hours on Wednesday, hitting $7.33. The stock had a trading volume of 266,697 shares, compared to its average volume of 283,970. The stock's 50-day moving average price is $6.83 and its 200-day moving average price is $6.07. MeiraGTx has a 12-month low of $3.85 and a 12-month high of $8.75. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $578.01 million, a P/E ratio of -6.06, a price-to-earnings-growth ratio of 0.37 and a beta of 1.23.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%. The company had revenue of $21.39 million during the quarter, compared to analysts' expectations of $1.50 million.

Remove Ads

Insider Activity at MeiraGTx

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total transaction of $150,960.00. Following the completion of the sale, the chief financial officer now directly owns 849,947 shares in the company, valued at approximately $5,346,166.63. The trade was a 2.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Alexandria Forbes sold 35,839 shares of the firm's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the completion of the transaction, the chief executive officer now owns 1,395,102 shares in the company, valued at approximately $9,026,309.94. This trade represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by insiders.

Institutional Trading of MeiraGTx

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in shares of MeiraGTx by 142.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company's stock valued at $39,000 after purchasing an additional 5,476 shares during the period. Knoll Capital Management LLC purchased a new position in shares of MeiraGTx in the third quarter worth approximately $5,212,000. Erste Asset Management GmbH bought a new stake in MeiraGTx during the third quarter valued at approximately $2,795,000. Garden State Investment Advisory Services LLC purchased a new stake in MeiraGTx during the third quarter valued at approximately $1,636,000. Finally, State Street Corp raised its position in MeiraGTx by 0.9% in the third quarter. State Street Corp now owns 574,727 shares of the company's stock worth $2,397,000 after acquiring an additional 5,251 shares during the period. Hedge funds and other institutional investors own 67.48% of the company's stock.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.